The U.S. Senate passed a revised Biosecure Act as an amendment to the National Defense Authorization Act, advancing legislation that would restrict federal funding and contracting with certain foreign biotechnology firms deemed companies of concern. The amendment rearranges earlier, more explicit lists of named companies and aims to broaden national security controls over access to biotech services and manufacturing. Commentators and industry groups warned the measure could strain research collaborations, supply chains and company operations while proponents argued it addresses national‑security risks from dual‑use capabilities. The vote sets up a conference with the House, where versions differ, and keeps the industry on alert for compliance and contracting changes resulting from final reconciliation.